{"id":"NCT01818596","sponsor":"Gilead Sciences","briefTitle":"Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment","officialTitle":"A Phase 3 Open-label Safety Study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1 Positive Patients With Mild to Moderate Renal Impairment","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-03-27","primaryCompletion":"2014-07-31","completion":"2018-07-18","firstPosted":"2013-03-26","resultsPosted":"2016-02-18","lastUpdate":"2020-03-02"},"enrollment":252,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["HIV","HIV Infections"],"interventions":[{"type":"DRUG","name":"E/C/F/TAF","otherNames":["Genvoya®"]}],"arms":[{"label":"E/C/F/TAF","type":"EXPERIMENTAL"}],"summary":"The primary objective of this study is to evaluate the effect of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) tablet on renal parameters at Week 24 in treatment-naive and treatment-experienced HIV-positive, adults with mild to moderate renal impairment.","primaryOutcome":{"measure":"Change From Baseline in the Estimated Glomerular Filtration Rate Calculated by the Cockcroft-Gault Formula (eGFR_CG) at Week 24","timeFrame":"Baseline; Week 24","effectByArm":[{"arm":"Cohort 1 (Treatment-experienced)","deltaMin":55.6,"sd":null},{"arm":"Cohort 2 (Treatment-naive)","deltaMin":60.2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":13},"locations":{"siteCount":70,"countries":["United States","Australia","Dominican Republic","France","Mexico","Netherlands","Spain","Thailand","United Kingdom"]},"refs":{"pmids":["26627107","27673443"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":55,"n":242},"commonTop":["Upper respiratory tract infection","Bronchitis","Arthralgia","Diarrhoea","Back pain"]}}